InSilicoTrials Verified Customer Reviews (2026)

AlisQI is a Quality Management platform built for process and batch manufacturers who want operational control without adding administrative overhead. Where many QMS platforms were designed around document storage and event tracking, AlisQI was architected as a data-first system. Quality, laboratory, and production data are structured and connected in a single operational backbone. This enables teams to see deviations earlier, understand performance trends in context, and act before issues escalate into waste, rework, or customer complaints. The platform includes modular capabilities across document control, training, deviations, CAPA, audits, risk management, supplier quality, SPC, and EHS. These capabilities are deployed through focused, ready-to-use Solvers that combine workflows, logic, dashboards, and analytics to address specific operational challenges without unnecessary scope. Because the system is built on structured, connected data, manufacturers can apply practical AI directly inside their workflows. This includes automated extraction of supplier COA data without predefined templates, conversational access to quality records, intelligent rule generation, and pattern recognition across incidents to strengthen corrective action effectiveness. Solvers are production-ready from the outset and evolve as products, processes, or sites change. Improvements do not require custom development or large IT programs, allowing organizations to modernize quality step by step. Manufacturers across chemicals, plastics, packaging, food and beverage, automotive, and industrial sectors use AlisQI to reduce firefighting, increase predictability, strengthen compliance, and turn quality data into operational intelligence.

SPEC Innovations offers a premier model-based systems engineering solution aimed at helping your team accelerate time-to-market, lower expenses, and reduce risks, even when dealing with the most intricate systems. This solution is available in both cloud-based and on-premise formats, featuring an easy-to-use graphical interface that can be accessed via any current web browser. Innoslate provides an extensive range of lifecycle capabilities, which include: • Management of Requirements • Document Control • System Modeling • Simulation of Discrete Events • Monte Carlo Analysis • Creation of DoDAF Models and Views • Management of Databases • Test Management equipped with comprehensive reports, status updates, outcomes, and additional features • Real-Time Collaboration Additionally, it encompasses numerous other functionalities to enhance workflow efficiency.

Our cutting-edge AI platform is transforming the drug discovery landscape, allowing us to create high-quality medications more rapidly than ever before. Backed by a wide array of discovery assets, both independently owned and co-developed with partners, and supported by prestigious investors, we are making considerable advancements in the sector. Atomwise has developed a machine-learning discovery engine that harnesses the power of convolutional neural networks in conjunction with vast chemical libraries to pinpoint new small-molecule drugs. The true potential of AI in revolutionizing drug discovery is rooted in the dedication and expertise of our team. We are committed to developing state-of-the-art AI tools that enhance the discovery of small molecules, targeting some of the most challenging and seemingly impossible objectives while optimizing the overall drug development process. By increasing computational efficiency, we can digitally screen trillions of compounds, significantly improving the likelihood of successful outcomes. Our models have achieved exceptional accuracy, effectively reducing the occurrence of false positives and setting the stage for groundbreaking medical innovations. As we continue to refine our technology, our ultimate goal is to equip researchers with the necessary tools to inspire innovation and deliver impactful results in the realm of drug discovery. This commitment to advancing the field is at the core of our mission.